A Phase II/III, Randomized, Single Blinded, Active Controlled Study to Evaluate the Immunogenicity and Safety of Inactivated Japanese encephalitis Vaccine in healthy volunteers.

Trial Profile

A Phase II/III, Randomized, Single Blinded, Active Controlled Study to Evaluate the Immunogenicity and Safety of Inactivated Japanese encephalitis Vaccine in healthy volunteers.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Therapeutic Use
  • Acronyms JENVAC
  • Sponsors Bharat Biotech
  • Most Recent Events

    • 04 Oct 2013 Primary endpoint 'Seroconversion-rate' has been met according to the Bharat Biotech media release.
    • 04 Oct 2013 Primary endpoint 'Neutralising-antibody-levels' has been met according to the Bharat Biotech media release.
    • 04 Oct 2013 Primary endpoint 'Geometric-mean-antibody-titre' has been met according to the Bharat Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top